Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideki Suganami

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Acta Ophthalmologica|December 10, 2014
Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover studyHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
Statistical Applications in Genetics and Molecular Biology|December 4, 2009
Statistical screening method for genetic factors influencing susceptibility to common diseases in a two-stage genome-wide association studyYasunori Sato, Nan Laird, Hideki Suganami, et al.
Journal of Diabetes Investigation|January 17, 2025
Post-hoc analysis of the tofogliflozin post-marketing surveillance study (J-STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMIHiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, et al.
JAMA Ophthalmology|April 17, 2015
Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical TrialsHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
American Journal of Ophthalmology|November 21, 2022
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical TrialsHidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Journal of Diabetes Investigation|April 30, 2019
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical studyYasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, et al.
Cardiovascular Diabetology|May 5, 2021
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trialsKoutaro Yokote, Shizuya Yamashita, Hidenori Arai, et al.
Acta Ophthalmologica|September 5, 2015
One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertensionHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
International Journal of Molecular Sciences|November 9, 2019
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin CombinationShizuya Yamashita, Hidenori Arai, Koutaro Yokote, et al.
Alzheimer Disease and Associated Disorders|July 7, 2026
Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer DiseaseYu Nakamura, Takuma Tsushio, Masaya Tanahashi, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Acta Ophthalmologica|December 10, 2014
Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover studyHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
Statistical Applications in Genetics and Molecular Biology|December 4, 2009
Statistical screening method for genetic factors influencing susceptibility to common diseases in a two-stage genome-wide association studyYasunori Sato, Nan Laird, Hideki Suganami, et al.
Journal of Diabetes Investigation|January 17, 2025
Post-hoc analysis of the tofogliflozin post-marketing surveillance study (J-STEP/LT): Tofogliflozin improves liver function in type 2 diabetes patients regardless of BMIHiroyuki Uchinuma, Mitsunori Matsushita, Masaya Tanahashi, et al.
JAMA Ophthalmology|April 17, 2015
Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical TrialsHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
American Journal of Ophthalmology|November 21, 2022
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical TrialsHidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, et al.
Journal of Diabetes Investigation|April 30, 2019
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical studyYasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, et al.
Cardiovascular Diabetology|May 5, 2021
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trialsKoutaro Yokote, Shizuya Yamashita, Hidenori Arai, et al.
Acta Ophthalmologica|September 5, 2015
One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertensionHidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, et al.
International Journal of Molecular Sciences|November 9, 2019
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin CombinationShizuya Yamashita, Hidenori Arai, Koutaro Yokote, et al.
Alzheimer Disease and Associated Disorders|July 7, 2026
Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer DiseaseYu Nakamura, Takuma Tsushio, Masaya Tanahashi, et al.
Pageof 7